Efficacy of prothrombin complex concentrate in intracranial hemorrhage patients under anticoagulant therapy

Efficacy of prothrombin complex concentrate in intracranial hemorrhage patients under anticoagulant therapy - Prothrombin complex concentratein intracranial hemorrhage patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021066

Enrollment

Registered

2016-02-17

Start date

2016-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracranial hemorrhage

Interventions

Intravenous administration of Prothrombin complex concentrate (500-1000 unit) and Vitamin K 10mg A dose of PCC PT-INR 2.0-2.9

500 unit PT-INR 3.0&gt

1000 unit

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Intracranial hemorrhage within 24 hours after onset and INR value more than 2.0 under warfarin therapy

Exclusion criteria

Exclusion criteria: Patients with contraindication for complex concentrate and Vitamin K Patients with fatal intracranial hemorrhage Inappropriate patients for this study judged by the physicians.

Design outcomes

Primary

Measure	Time frame
PT-INR value at 30 minutes after infusion of prothrombin complex concentrate	—

Secondary

Measure	Time frame
expansion of hematoma	—

Countries

Japan

Contacts

Public ContactTomoyuki Ohara

Kyoto Prefectural University of Medicine Neurology

ohatomo@koto.kpu-m.ac.jp075-251-5793

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026